Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alkaline topical paste versus salicylic acid for common cutaneous warts
IRCT20260922071156N1Phase 3Not yet recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Salvax in common wart (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Change in wart area, Time to complete wart clearance and 3 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Salvax
03
Conditions
common wart
Beyond the preview
Go deeper on IRCT20260922071156N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260922071156N1.